GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TG Therapeutics Inc.
Shares of TG Therapeutics, a biotech company focused on treating autoimmune diseases and cancer, are highly volatile. Their price depends on the commercial success of its approved drugs and news from clinical trials, creating binary risks for investors.
Share prices of companies in the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases and cancer. We classify it in the Cancer Blood sector. The chart below shows the overall performance of this biotech segment, not just TGTX stock.
Broad Market Index - GURU.Markets
TG Therapeutics is a biopharmaceutical company focused on developing treatments for multiple sclerosis and cancer. As an innovative healthcare company, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it to TGTX shares to assess the outlook for the biotech sector.
Change in the price of a company, segment, and market as a whole per day
TGTX - Daily change in the company's share price TG Therapeutics Inc.
The volatility of TG Therapeutics (TGTX), a biopharmaceutical company focused on blood cancer and autoimmune diseases, is reflected in Change_Co, which is highly sensitive to clinical results and FDA approvals. Change_Co is a measure of the extreme volatility inherent in innovative biopharma. In System.GURU.Markets formulas, it is important for risk modeling.
Daily change in the price of a set of shares in a market segment - Cancer blood
TG Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with TGTX, which focuses on multiple sclerosis and cancer treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
TG Therapeutics is a biopharmaceutical company specializing in drugs for the treatment of multiple sclerosis and cancer. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing TG Therapeutics' stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TG Therapeutics Inc.
TG Therapeutics is a biotech company with a successful pipeline of drugs in oncology and autoimmune diseases. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Cancer blood
TG Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of multiple sclerosis and cancer. Its success depends on the commercialization of its first approved drug. The chart shows how the market perceives the potential of its drugs and how they progress to the commercial stage.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Following the successful launch of its multiple sclerosis drug, TG Therapeutics has entered a commercial growth phase. Its stock price now depends on sales growth rather than research news. This chart tells the story of the biotech startup's transformation into a fully-fledged pharmaceutical company.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TG Therapeutics Inc.
TG Therapeutics, a biopharmaceutical company focused on treating autoimmune diseases and cancer, shows sharp monthly fluctuations reflecting sales data for its key drug, as well as news about clinical trials and regulatory decisions on new indications.
Monthly dynamics of market capitalization of the market segment - Cancer blood
This chart reflects the dynamics of the biotech sector. For TG Therapeutics, an oncology company, it's the backdrop. Its movements illustrate how a successful launch of a new drug and its commercial success can dramatically alter a company's trajectory in a volatile sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
TG Therapeutics, Inc. is a commercial biopharmaceutical company focused on developing and marketing treatments for multiple sclerosis and cancer. The company's future depends on the successful commercialization of its drugs. The broader market chart serves only as a backdrop to understand how its performance and regulatory announcements impacted its shares, regardless of overall sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TG Therapeutics Inc.
TG Therapeutics is a biotech company focused on treating autoimmune diseases and blood cancers. Its weekly stock price is highly volatile, dependent on FDA decisions and clinical trial data. The chart reflects the high stakes and binary risks inherent in innovative pharmaceuticals.
Weekly dynamics of market capitalization of the market segment - Cancer blood
TG Therapeutics is part of the volatile biotech sector, where sentiment can shift across the entire industry. Key FDA decisions or scientific breakthroughs can lift or derail the entire segment. The chart shows how the company compares to the overall biotech industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
TG Therapeutics is a biotech company that has achieved success in treating multiple sclerosis. Its shares can move on sales and research news. The chart will show how independent the company is from the broader market. Are its weekly fluctuations the result of its own events or general market panic?
Market capitalization of the company, segment and market as a whole
TGTX - Market capitalization of the company TG Therapeutics Inc.
The TG Therapeutics market capitalization curve is a dramatic biotech story. The chart vividly illustrates how a market valuation can soar on anticipation of a new drug and collapse due to regulatory setbacks or safety data. It's a visualization of the high risks and rewards of pharma.
TGTX - Share of the company's market capitalization TG Therapeutics Inc. within the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on the treatment of multiple sclerosis and cancer. Its market capitalization share is a barometer of the commercial success of its drugs. This chart shows how new drug approvals and sales data dramatically alter its standing among pharmaceutical giants.
Market capitalization of the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases and blood cancers. How big is this arena? The chart below shows the overall market capitalization of the oncology sector. Its growth reflects massive investments and scientific advances in the search for new treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
The TG Therapeutics chart shows the dramatic story of a biotech company. Its market capitalization is a roller coaster ride, where the approval of one drug (for multiple sclerosis) and the failure of another (in oncology) radically alter the market valuation. This chart demonstrates how one success can outweigh everything else.
Book value capitalization of the company, segment and market as a whole
TGTX - Book value capitalization of the company TG Therapeutics Inc.
TG Therapeutics's primary value lies in its drug portfolio, but its book value reveals the tangible side of the business: R&D centers, manufacturing contracts, and significant financial reserves for clinical trials. The chart below shows how the company built its physical and financial capital.
TGTX - Share of the company's book capitalization TG Therapeutics Inc. within the market segment - Cancer blood
TG Therapeutics is a biotechnology company whose tangible assets are concentrated in R&D centers and laboratories focused on oncology. These high-tech facilities are its physical platform for developing new drugs. The chart shows the share of this specialized scientific infrastructure in its segment.
Market segment balance sheet capitalization - Cancer blood
TG Therapeutics is a biotech company focused on commercializing its drugs. This requires investment in marketing, but makes it less capital-intensive than giants with dozens of manufacturing plants. The graph below illustrates the scale of the pharmaceutical sector, highlighting its business model.
Book value of all companies included in the broad market index - GURU.Markets
TG Therapeutics develops drugs to treat autoimmune diseases and blood cancers. Its book value is small, but it represents capital for breakthrough research. This stake in BCap_All is the material foundation on which hope is built for thousands of patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TG Therapeutics Inc.
TG Therapeutics is a biotech company. Its book value is close to zero compared to its market value. This gap represents the market valuation of its drug, Briumvi, which has already been approved and has the potential to become a blockbuster. The P/B ratio here represents the monetization of successful R&D.
Market to book capitalization ratio in a market segment - Cancer blood
TG Therapeutics specializes in treating oncology and autoimmune diseases. Like many biotech companies, its valuation is determined by the potential of its drugs. This metric represents a significant premium to book value, reflecting investor expectations for approval and commercial success of its developments.
Market to book capitalization ratio for the market as a whole
TG Therapeutics is a biopharmaceutical company focused on the treatment of autoimmune diseases, specifically multiple sclerosis. Compared to average market valuations, as shown in this chart, its valuation reflects the commercial success of its approved drug and investor expectations for its continued market penetration.
Debts of the company, segment and market as a whole
TGTX - Company debts TG Therapeutics Inc.
TG Therapeutics, a biopharmaceutical company focused on treating oncology and autoimmune diseases, uses debt financing to bring its drugs to market. The capital is needed to conduct final-stage clinical trials, complete regulatory procedures, and build the commercial infrastructure to launch sales.
Market segment debts - Cancer blood
TG Therapeutics is a biotech company focused on treating autoimmune diseases and blood cancers. Bringing a new drug to market requires significant investment in clinical trials. The company's financial structure, shown in this chart, shows whether it has chosen equity or debt to finance its expensive developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TG Therapeutics Inc.
TG Therapeutics is a biopharmaceutical company focused on treating oncology and autoimmune diseases. Its success depends on the results of clinical trials. This chart shows how the company finances its expensive research. The absence of significant debt suggests a focus on equity, reducing the risk of bankruptcy before drug approval.
Market segment debt to market segment book capitalization - Cancer blood
TG Therapeutics specializes in developing treatments for B-cell diseases, including blood cancer and autoimmune disorders. This chart shows the overall debt burden in the biotech sector. It helps understand how the industry finances expensive clinical trials and how TGTX's financial strategy compares to this trend.
Debt to book value of all companies in the market
TG Therapeutics, a biopharmaceutical company, requires significant capital for clinical trials. This chart shows the overall level of debt in the market, reflecting investors' willingness to finance risk. For TGTX, this provides an important context: how easy is it to raise funds for innovative projects when the overall market is becoming more or less leveraged?
P/E of the company, segment and market as a whole
P/E - TG Therapeutics Inc.
TG Therapeutics is a biopharmaceutical company focused on the treatment of multiple sclerosis and cancer. This chart shows that the company's valuation depends on the commercial success of its approved drugs and the potential of future developments. Investors analyze sales trends and clinical trial news, not just current profits.
P/E of the market segment - Cancer blood
The biopharmaceutical sector, where TG Therapeutics has achieved commercial success, is valued based on sales and future potential. This chart shows the average valuation for profitable biotechs. It allows investors to understand how the market values TG's current drug sales and research pipeline compared to competitors.
P/E of the market as a whole
TG Therapeutics is a biopharmaceutical company focused on the treatment of multiple sclerosis and cancer. Its valuation depends entirely on the commercial success of its approved drugs and the results of new drug candidates. Overall market sentiment, reflected in this chart, is irrelevant compared to sales data and regulatory announcements.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TG Therapeutics Inc.
TG Therapeutics is a biopharmaceutical company focused on treating multiple sclerosis and cancer. This chart reflects analyst expectations regarding the commercial success of its recently approved drugs. It shows whether experts believe the company can successfully compete in the market and achieve significant sales.
%20P%2FE%20TG%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TG-Therapeutics-Inc.&v=1772647244484 "Chart of the company's future (projected) P/E TG Therapeutics Inc.")
Future (projected) P/E of the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on developing treatments for multiple sclerosis and cancer. This indicator compares the company's profitability expectations with those of the biotech sector. It assesses how the market perceives the commercial potential of its approved drugs and the prospects for clinical development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772647244535 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases and blood cancers. This chart shows the company's overall risk appetite. For TGTX, clinical trial results and drug approvals are fundamental. A positive market environment facilitates capital raising but is not a guarantee of long-term success.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772647244586 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TG Therapeutics Inc.
TG Therapeutics is a biopharmaceutical company specializing in the development of treatments for B-cell diseases, including multiple sclerosis and oncology. This chart shows the company's financial trajectory from development to commercialization. The progress reflects the market success of its drugs, sales volumes, and ongoing investment in research.
Profit of companies in the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of B-cell diseases, particularly multiple sclerosis and oncology. This chart shows the total profitability of the biotech sector, reflecting the success of companies in completing clinical trials and bringing new drugs to market.
Overall market profit
TG Therapeutics is a biopharmaceutical company specializing in the treatment of cancer and autoimmune diseases. Its value is determined by the success of its drugs on the market and in clinical trials. The company's business is largely independent of economic cycles, but investor sentiment, influenced by the overall economic situation, can impact the availability of financing.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TG Therapeutics Inc.
TG Therapeutics is a pharmaceutical company that has achieved success with a drug for the treatment of multiple sclerosis. Now its future depends on how successfully it can commercialize this product. This chart reflects analyst expectations for sales growth and the company's achievement of stable profitability.
%20profit%20of%20the%20company%20TG%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TG-Therapeutics-Inc.&v=1772647244679 "Graph of future (projected) profit of the company TG Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on developing treatments for multiple sclerosis and B-cell cancers. This chart shows the outlook for the biotech sector. The recent approval of its key drug for multiple sclerosis completely changes the company's outlook, transforming it from a research-based company to a commercial one.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772647244688 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
TG Therapeutics specializes in the treatment of multiple sclerosis and cancer. Demand for its drugs is driven by medical needs, not the economic cycle. However, the overall profit expectations reflected in the chart are important. They influence financial markets, the availability of capital for R&D, and strategic partnership decisions by large pharmaceutical companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772647244701 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TG Therapeutics Inc.
TG Therapeutics is a biopharmaceutical company focused on drugs for the treatment of multiple sclerosis and blood cancers. This chart shows how the company's valuation is influenced by the commercial success of its approved drugs and clinical development news. It reflects investor expectations for peak sales.
P/S market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on the treatment of multiple sclerosis and cancer. Successful drug launches are a key revenue driver. This chart shows the average valuation in biotech companies, providing insight into how the market views the commercial potential of TG Therapeutics' products compared to peers.
P/S of the market as a whole
TG Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of multiple sclerosis and blood cancers. Its valuation is directly dependent on the success of clinical trials and drug commercialization. This market valuation chart clearly illustrates the gap between the value of biotech hopes and current revenue valuations.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TG Therapeutics Inc.
TG Therapeutics is a biopharmaceutical company focused on the treatment of multiple sclerosis and cancer. This chart shows investor expectations for future sales. It is directly dependent on the commercialization success of already approved drugs and progress in clinical trials of new candidates, which determines the company's long-term prospects.
%20P%2FS%20TG%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TG-Therapeutics-Inc.&v=1772647245131 "The graph of the company's future (projected) P/S TG Therapeutics Inc.")
Future (projected) P/S of the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company whose multiple sclerosis drug has become an important new treatment option. This chart compares the company's future revenue expectations with its industry. It reflects the market's assessment of the drug's commercial potential and its ability to compete in the highly competitive MS market.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772647245138 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
TG Therapeutics is a biopharmaceutical company focused on drugs for the treatment of multiple sclerosis and oncology. This chart reflects confidence in future growth, with biotechnology playing a key role. TG Therapeutics' success in bringing new treatments to market demonstrates how scientific breakthroughs create entirely new markets and revenue streams.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772647245169 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TG Therapeutics Inc.
TG Therapeutics is a commercial biopharmaceutical company focused on the treatment of B-cell diseases, including multiple sclerosis. This chart shows the revenue from sales of its approved drugs. This indicator's dynamics directly indicate the successful launch of a drug and its acceptance by the medical community.
Sales of companies in the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on the treatment of autoimmune diseases and blood cancers. The successful launch of their drugs is the culmination of years of research. This graph reflects the dynamics of the entire segment, where the commercialization of a single innovative drug can dramatically change the revenue and prospects of the entire industry.
Overall market sales
TG Therapeutics, Inc. is focused on developing treatments for oncology and autoimmune diseases. Its success depends on progress in clinical trials and the investment climate. Periods of growth in total revenues, reflected in the graph, facilitate capital inflows into the biotech sector, allowing companies like TGTX to fund expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TG Therapeutics Inc.
TG Therapeutics is a biopharmaceutical company focused on developing treatments for multiple sclerosis and B-cell oncology. The sales forecast reflects market expectations for the commercial success of its key drug. It shows how analysts assess its acceptance by the medical community and the competition in these therapeutic areas.
%20sales%20of%20the%20company%20TG%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TG-Therapeutics-Inc.&v=1772647245372 "Schedule of future (projected) sales of the company TG Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on developing treatments for multiple sclerosis and hematologic oncology. The company's success depends on the approval and commercialization of its key products. This chart shows forecasts for the pharmaceutical sector, allowing one to assess the potential contribution of TG's products to the overall picture.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772647245416 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
TG Therapeutics, which focuses on treating autoimmune diseases and blood cancers, views this chart as a marker for the state of the healthcare system. The improved economic outlook reflected here means greater stability in the budgets of insurance companies and hospitals, facilitating patient access to new, innovative drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772647245444 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TG Therapeutics Inc.
TG Therapeutics is a biotech company focused on developing treatments for multiple sclerosis and cancer. After receiving approval for its drugs, the company transitions from R&D expenditures to revenue generation. This chart shows how successful commercialization is and how sales revenues begin to convert into net profit.
Market segment marginality - Cancer blood
TG Therapeutics is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of multiple sclerosis and cancer. This chart shows its financial performance in the context of the industry. Following the successful launch of a new drug, the company's profitability can soar, outperforming the industry average due to market exclusivity.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company TG Therapeutics Inc.
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases and blood cancers. This chart shows the team's growth, especially following the approval of its key drug. Increasing sales and marketing staff is a critical step in commercialization and bringing a drug to market.
Share of the company's employees TG Therapeutics Inc. within the market segment - Cancer blood
TG Therapeutics specializes in treating B-cell diseases, including multiple sclerosis and oncology. Its success depends on its team of scientists and clinicians. This chart shows the company's concentration of specialists in this narrow therapeutic area, a direct indicator of its scientific potential and focus on breakthrough research.
Number of employees in the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases and oncology. Its core asset is its scientific and clinical teams. This chart shows how the company is expanding to support its drugs. Headcount growth, particularly in the commercial department, is a key indicator of a successful new product launch.
Number of employees in the market as a whole
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases and blood cancers. Its growth depends on successful clinical trials and regulatory approval. Unlike the broader job market reflected in this chart, hiring at TG Therapeutics involves targeted investments in science and the development of drugs that can change patients' lives.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TG Therapeutics Inc. (TGTX)
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases and cancer. Its high market capitalization, despite its relatively small workforce, is the result of successfully launching new drugs. This chart shows how intellectual capital and successful clinical trials create enormous shareholder value.
%20of%20the%20company%20TG%20Therapeutics%20Inc.%20(TGTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TG-Therapeutics-Inc.-TGTX&v=1772647245876 "Chart of market capitalization per employee (in thousands of dollars) of the company TG Therapeutics Inc. (TGTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases (multiple sclerosis) and blood cancers. This chart shows the average capitalization per employee in the sector. It demonstrates the market's confidence in their approved drugs and scientific potential per employee.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772647245911 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
TG Therapeutics is a biopharmaceutical company focused on treating oncology and autoimmune diseases. Its value is determined by the market success of its drugs and its pipeline. This chart illustrates the high valuation per employee typical of a successful biotech company, where a single approved drug can generate billions in revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772647245963 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TG Therapeutics Inc. (TGTX)
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases and blood cancers. This chart demonstrates the effectiveness of their strategy. Following the approval of a key drug (Briumvi), this metric should rise sharply, demonstrating how a small team can bring a blockbuster to market and generate high profit per employee.
%20Chart%20TG%20Therapeutics%20Inc.%20(TGTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TG-Therapeutics-Inc.-TGTX&v=1772647246024 "Company Profit Per Employee (in thousands of dollars) Chart TG Therapeutics Inc. (TGTX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
TG Therapeutics (TGTX) is a biotech company with an approved drug (Briumvi) for multiple sclerosis. This chart shows the benchmark for "Blood Cancer" (Biotech). In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high. This is the "blockbuster business," where a single patent generates billions.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772647246142 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
TG Therapeutics (TGTX) is a biopharmaceutical company focused on developing treatments for B-cell-mediated diseases, particularly multiple sclerosis and cancer (leukemia). This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772647246213 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TG Therapeutics Inc. (TGTX)
TG Therapeutics is a biopharmaceutical company focused on treating autoimmune diseases and blood cancers. This chart is a history of commercializing scientific discoveries. After drug approval, it demonstrates how a small but highly effective team can generate significant revenue by bringing life-saving drugs to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TG-Therapeutics-Inc.-TGTX&v=1772647246287 "Sales chart per company employee TG Therapeutics Inc. (TGTX)")
Sales per employee in the market segment - Cancer blood
TG Therapeutics is a biopharmaceutical company focused on treating multiple sclerosis and cancer. This chart shows the average revenue per employee in this segment. For a biotech company at the commercialization stage, this is a critical indicator of how effectively their commercial team is bringing new drugs to market compared to competitors.
Sales per employee for the market as a whole
TG Therapeutics, Inc. focuses on treating autoimmune diseases (multiple sclerosis) and oncology. They successfully launched Briumvi. This chart reflects the conversion from R&D expenses to commercial revenue. It shows how effectively their commercial team generates revenue from a new drug per employee.
Short shares by company, segment and market as a whole
Shares shorted by company TG Therapeutics Inc. (TGTX)
TG Therapeutics is a biopharmaceutical company focused on treating multiple sclerosis and cancer. The company's success hinges on its drug, Briumvi. This chart shows the volume of short bets from investors who doubt Briumvi will be able to compete with established market leaders like Roche's Ocrevus, which will limit its sales.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TG-Therapeutics-Inc.-TGTX&v=1772647246374 "Short Shares Chart for the Company TG Therapeutics Inc. (TGTX)")
Shares shorted by market segment - Cancer blood
TG Therapeutics is a biotech company focused on the treatment of multiple sclerosis and hematological oncology. Their success depends on the approval and launch of their drugs. This chart reflects the overall pessimism in biotech. It shows how many investors overall doubt the commercial success of new drugs or fear regulatory barriers for the entire industry.
Shares shorted by the overall market
TG Therapeutics (TGTX) is a biotech focused on treating autoimmune diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk. This pessimism, visible on the chart, weighs on growth stocks like TGTX, even if they have an approved drug.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TG Therapeutics Inc. (TGTX)
TG Therapeutics is a biotech company focused on drugs for the treatment of autoimmune diseases and cancer. Its shares are volatile. This chart for TGTX can soar above 70 on positive news from the FDA. Below 30 is often associated with trial failures or competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TG-Therapeutics-Inc.-TGTX&v=1772647246457 "RSI 14 indicator chart for the company's stock TG Therapeutics Inc. (TGTX)")
RSI 14 Market Segment - Cancer blood
TG Therapeutics (TGTX) is a biotech company focused on treating multiple sclerosis (MS) and blood cancers. Their success depends on the approval and launch of new drugs. This chart measures the pulse of the Oncology/Neurology sector. It helps differentiate TGTX's performance from the overall "overheated" or "oversold" situation in the high-risk biotech sector.
RSI 14 for the overall market
TG Therapeutics is a biotech company focused on treating multiple sclerosis and cancer. Its success depends on regulatory approval and drug commercialization. This chart shows the overall risk appetite in biotech. In times of panic, investors tend to sell off shares of companies whose earnings are dependent on future events.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TGTX (TG Therapeutics Inc.)
TG Therapeutics is a biopharmaceutical company focused on the treatment of B-cell diseases, primarily multiple sclerosis (MS) and blood cancers (leukemia). This chart reflects the collective opinion of experts on the fair 12-month share price of TGTX, based on the success of its drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TGTX-TG-Therapeutics-Inc.&v=1772647246537 "A chart showing analyst consensus forecasts for the expected stock price. TGTX (TG Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price TGTX (TG Therapeutics Inc.)
TG Therapeutics is a biotech company that has achieved success with its drug Briumvi (ublituximab) for the treatment of multiple sclerosis. It is their key and only major product. This chart shows analysts' confidence in the drug's commercial success in a competitive market. It reflects the gap between the consensus estimate and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TGTX-TG-Therapeutics-Inc.&v=1772647246586 "A chart showing the difference between the consensus forecast and the actual stock price. TGTX (TG Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
TG Therapeutics is a biotech company that has achieved success with its drug Briumvi for the treatment of multiple sclerosis (MS). This chart shows analysts' overall expectations across the oncology and neuroscience sectors. It reflects whether experts believe the company will be commercially successful in the highly competitive MS market.
Analysts' consensus forecast for the overall market share price
TG Therapeutics (TGTX) is a biotech company that hit the jackpot with a drug for multiple sclerosis (MS). This chart, reflecting expert expectations, doesn't affect their demand (MS is always treatable). However, it does impact risk appetite. For TGTX, which needs to recoup its R&D costs, investor pessimism could weigh on the stock's valuation.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TG Therapeutics Inc.
TG Therapeutics is a biotech company that has achieved success with its drug Briumvi for the treatment of multiple sclerosis (MS). This chart is a commercialization indicator. It reflects how successfully the company is launching its drug in the highly competitive MS market, capturing market share from established giants (like Biogen).
AKIMA Market Segment Index - Cancer blood
TG Therapeutics is a biotech (R&D) company that (after setbacks in cancer) successfully relaunched itself with the approval of Briumvi, an innovative drug for multiple sclerosis (MS). This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark provides insight into how TGTX's successful pivot into neuroscience (MS) differentiates it from the average pharma company.
The AKIM Index for the overall market
TG Therapeutics is a biotech company focused on treating B-cell diseases (multiple sclerosis, blood cancer). It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends.
